Novo Nordisk looks to harness Septerna’s broader GPCR drug pathways, which include GLP-1, for obesity and diabetes treatments.
Source link
This biotech’s stock rockets on oral obesity drug partnership with Wegovy parent
-
By 100 Per Day
- May 14, 2025
Show Comments (0)
Hide Comments (0)
0
0
votes
Article Rating
Subscribe
Login
0 Comments
Oldest
Newest
Most Voted
Inline Feedbacks
View all comments
Recent Posts:
Colombian presidential candidate in critical condition after...
2views
0likes
0comments
-
By 100 Per Day
- June 8, 2025